Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Dermatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01163253
Completado
Fase 3
ClinicalTrials.gov
SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
INTERVENTIONAL
Inicio: 24 de oct de 2018
ID: NCT03574597
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
INTERVENTIONAL
Inicio: 20 de oct de 2018
ID: NCT03580356
Completado
Fase 3
ClinicalTrials.gov
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients
INTERVENTIONAL
Inicio: 1 de ago de 2014
ID: NCT02161562
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)
INTERVENTIONAL
Inicio: 30 de ene de 2023
ID: NCT05633355
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
INTERVENTIONAL
Inicio: 12 de oct de 2023
ID: NCT06095115
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
INTERVENTIONAL
Inicio: 12 de dic de 2019
ID: NCT04183335
Reclutando
ClinicalTrials.gov
Advanced Wireless Sensors for Neonatal Care in the Delivery Room: the AWARD Prospective Multicenter International Study
INTERVENTIONAL
Inicio: 8 de abr de 2025
ID: NCT06693817
Reclutando
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 16 de may de 2025
ID: NCT06947993
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)
INTERVENTIONAL
Inicio: 1 de mar de 2007
ID: NCT00423657
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
INTERVENTIONAL
Inicio: 27 de abr de 2017
ID: NCT03104400
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa
INTERVENTIONAL
Inicio: 18 de mar de 2020
ID: NCT04179175
Completado
Fase 3
ClinicalTrials.gov
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
INTERVENTIONAL
Inicio: 29 de oct de 2013
ID: NCT01959529
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema
INTERVENTIONAL
Inicio: 5 de ago de 2020
ID: NCT04432831
Reclutando
ClinicalTrials.gov
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin
INTERVENTIONAL
Inicio: 3 de nov de 2022
ID: NCT05575882
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection
INTERVENTIONAL
Inicio: 1 de feb de 2007
ID: NCT00424190
Completado
Fase 3
ClinicalTrials.gov
A Multi-centre, Multinational, Open-labelled, Randomised, Parallel-Group Comparison of Insulin Detemir Plus Insulin Aspart With NPH Insulin Plus Human Soluble Insulin in Subjects With Type 1 Diabetes on a Basal-Bolus Regimen
INTERVENTIONAL
Inicio: 1 de mar de 2002
ID: NCT01486940
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)
INTERVENTIONAL
Inicio: 2 de dic de 2013
ID: NCT01885208
Completado
Fase 3
ClinicalTrials.gov
NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1)
INTERVENTIONAL
Inicio: 1 de feb de 2010
ID: NCT01074268
Terminado
ClinicalTrials.gov
AO Multicenter Intervention Trial to Evaluate the Impact of a Bundle of Measures for the Prevention of Surgical Site Infection in Fracture Patients
INTERVENTIONAL
Inicio: 6 de dic de 2019
ID: NCT03380273
Anterior
1
...
5
6
7
...
434
Siguiente
Filtros